CEREBYX DIN 02230988
Health Canada record
| Active ingredient(s) | FOSPHENYTOIN SODIUM 75 MG |
|---|---|
| Dosage form | Solution |
| Route | Intravenous; Intramuscular |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | N03AB05 FOSPHENYTOIN |
| Original market date | 01-Mar-2000 |
| Current status date | 07-Oct-2022 |
| Source | Health Canada DPD |
Establishment licence of the holder
Searchlight Pharma Inc — licence 102247, currently licensed, last inspection rating C (2024-10-10).
No Canadian shortage report is currently matched to this DIN.
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 29166 | 2022-10-07 | New Drug Submission (NDS) | Administrative: Change in Product Ownership |
| 7233 | 2005-07-12 | New Drug Submission (NDS) | MANUFACTURER NAME CHANGE |
| 2284 | 2001-01-17 | New Drug Submission (NDS) | MANUFACTURER NAME CHANGE |
| 3825 | 1997-03-20 | New Drug Submission (NDS) |
International API supply for FOSPHENYTOIN SODIUM
5 active FDA Drug Master Files.
Request a quote for CEREBYX